| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Randy J. Seeley | Q38546582 |
| P2093 | author name string | David A D'Alessio | |
| Darleen A Sandoval | |||
| Jason G Barrera | |||
| P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
| Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | Q28117412 | ||
| The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness | Q28216072 | ||
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | Q28571689 | ||
| Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats | Q28578291 | ||
| Role of leptin in the regulation of glucagon-like peptide-1 secretion | Q28609244 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| Immune challenge and satiety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate parallel pathways for viscerosensory signaling | Q30434461 | ||
| Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure | Q30478488 | ||
| Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. | Q33518270 | ||
| Incretin-based therapies: review of current clinical trial data. | Q33537570 | ||
| Meal-anticipatory glucagon-like peptide-1 secretion in rats. | Q33634407 | ||
| Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? | Q33789529 | ||
| Leptin action in the forebrain regulates the hindbrain response to satiety signals. | Q33830700 | ||
| Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system | Q33840311 | ||
| Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats | Q34020617 | ||
| Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. | Q48714353 | ||
| Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus | Q48883013 | ||
| Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake | Q48883932 | ||
| Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats | Q48905629 | ||
| Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Q51385774 | ||
| Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. | Q51484711 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. | Q51495176 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin. | Q51552340 | ||
| The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. | Q52087168 | ||
| Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. | Q52522147 | ||
| Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. | Q52528278 | ||
| The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity | Q58448710 | ||
| Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men | Q58448899 | ||
| Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites | Q70905833 | ||
| Entry of exendin-4 into brain is rapid but may be limited at high doses | Q73107463 | ||
| Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA | Q73525124 | ||
| Chemical characterization of leptin-activated neurons in the rat brain | Q73925838 | ||
| Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4 | Q74102795 | ||
| No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man | Q74349977 | ||
| Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite | Q79707998 | ||
| Is parental control over children's eating associated with childhood obesity? Results from a population-based sample of third graders | Q95816322 | ||
| A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. | Q34343581 | ||
| Attenuated GLP-1 secretion in obesity: cause or consequence? | Q34409856 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Glucagon-like peptide-1: a potent regulator of food intake in humans | Q35565562 | ||
| Gastrointestinal satiety signals II. Cholecystokinin | Q35625486 | ||
| Insulin and leptin as adiposity signals. | Q35641866 | ||
| Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats | Q36415844 | ||
| Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice | Q36587611 | ||
| Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation | Q36796571 | ||
| Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake | Q36807579 | ||
| Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity | Q36906298 | ||
| Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing | Q36906311 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study | Q36975695 | ||
| Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. | Q36979291 | ||
| Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms | Q37125945 | ||
| Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. | Q37136936 | ||
| Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress | Q37153737 | ||
| Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling | Q37210752 | ||
| The effects of GLP-1 infusion in the hepatic portal region on food intake | Q37343491 | ||
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
| Hindbrain leptin receptor stimulation enhances the anorexic response to cholecystokinin. | Q37422077 | ||
| Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats | Q37429168 | ||
| Molecular mechanisms underlying nutrient-stimulated incretin secretion | Q37667168 | ||
| Central leptin modulates behavioral and neural responsivity to CCK. | Q38324994 | ||
| Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents | Q38342036 | ||
| Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage | Q40035788 | ||
| Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats | Q40116707 | ||
| Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever | Q40608432 | ||
| Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. | Q40657491 | ||
| Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence | Q40998534 | ||
| The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. | Q41718186 | ||
| Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. | Q42445138 | ||
| Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. | Q42453890 | ||
| Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like Peptide 1 neurons | Q42684124 | ||
| Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor | Q43069245 | ||
| Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus | Q43104660 | ||
| Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist | Q43182574 | ||
| Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 | ||
| Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus | Q44467072 | ||
| CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. | Q44516249 | ||
| Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells | Q44758175 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway | Q46464837 | ||
| Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice | Q46525214 | ||
| Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. | Q46538045 | ||
| Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes | Q46691051 | ||
| An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis | Q46723219 | ||
| Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients | Q46830628 | ||
| Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice | Q46956823 | ||
| Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons. | Q46985999 | ||
| Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures | Q46988910 | ||
| Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats | Q47235596 | ||
| Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats | Q47238177 | ||
| Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. | Q47255637 | ||
| Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. | Q47273005 | ||
| The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. | Q47282831 | ||
| Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice | Q47286337 | ||
| Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. | Q47295180 | ||
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
| Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. | Q47308234 | ||
| GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats | Q47442436 | ||
| Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity | Q47868205 | ||
| Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats | Q47873900 | ||
| Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse | Q48082829 | ||
| Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus | Q48138420 | ||
| Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei | Q48204065 | ||
| Identification and localization of glucagon-like peptide-1 and its receptor in rat brain | Q48216174 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons | Q48262019 | ||
| Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system | Q48306367 | ||
| Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons | Q48325811 | ||
| Upregulation of the brainstem preproglucagon system in the obese Zucker rat. | Q48374736 | ||
| Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats | Q48434817 | ||
| Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats | Q48456704 | ||
| PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats | Q48540815 | ||
| Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. | Q48608104 | ||
| A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans | Q48664995 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 507-516 | |
| P577 | publication date | 2011-06-07 | |
| P1433 | published in | Nature Reviews Endocrinology | Q2079257 |
| P1476 | title | GLP-1 and energy balance: an integrated model of short-term and long-term control | |
| P478 | volume | 7 |
| Q35915760 | A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women |
| Q48246762 | A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents |
| Q39015682 | A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion |
| Q46570456 | Acute activation of GLP-1-expressing neurons promotes glucose homeostasis and insulin sensitivity |
| Q37527258 | Adropin deficiency is associated with increased adiposity and insulin resistance |
| Q41169706 | Adropin deficiency worsens HFD-induced metabolic defects |
| Q49677696 | Alfalfa-containing diets alter luminal microbiota structure and short chain fatty acid sensing in the caecal mucosa of pigs |
| Q36926355 | An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes |
| Q57179222 | Battle of GLP-1 delivery technologies |
| Q51744991 | Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. |
| Q38095437 | CNS control of glucose metabolism: response to environmental challenges |
| Q36484283 | Cardiovascular biology of the incretin system |
| Q39146023 | Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides |
| Q51041822 | Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. |
| Q48300731 | DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain |
| Q37699321 | Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways |
| Q38542686 | Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function |
| Q35599917 | Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis |
| Q36684108 | Effects of exercise training on gut hormone levels after a single bout of exercise in middle-aged Japanese women |
| Q36983097 | Effects of late gestational high-fat diet on body weight, metabolic regulation and adipokine expression in offspring |
| Q36993549 | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
| Q48250188 | Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial |
| Q35769584 | Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia. |
| Q35948898 | Exendin-4 decreases amphetamine-induced locomotor activity |
| Q42207255 | Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats. |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q35920772 | Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis |
| Q26828589 | From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior |
| Q101051267 | Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system |
| Q35200252 | GLP-1 based therapeutics: simultaneously combating T2DM and obesity. |
| Q37629291 | GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents |
| Q58763580 | GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca channels |
| Q38238288 | GLP-1: benefits beyond pancreas. |
| Q38208929 | Gastrointestinal hormones and polycystic ovary syndrome |
| Q47271304 | Gender-specific alteration of energy balance and circadian locomotor activity in the Crtc1 knockout mouse model of depression. |
| Q49997196 | Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q90260620 | Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function |
| Q42936904 | Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight |
| Q45034178 | Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model |
| Q33838133 | Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure |
| Q30235568 | Gut-Brain Cross-Talk in Metabolic Control |
| Q35029601 | Gut-brain mechanisms controlling glucose homeostasis |
| Q38923365 | Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives |
| Q37054716 | High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. |
| Q38311585 | Hormones and diet, but not body weight, control hypothalamic microglial activity |
| Q92932843 | Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation |
| Q36442462 | Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcinoembryonic Antigen-related Cell Adhesion Molecule 2 (CEACAM2). |
| Q38787756 | Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. |
| Q46198155 | Insulin-independent actions of glucagon-like peptide-1 in wethers |
| Q28507260 | Insulin-like peptide 5 is an orexigenic gastrointestinal hormone |
| Q64910238 | Interventions for the Treatment of Craniopharyngioma-Related Hypothalamic Obesity: A Systematic Review. |
| Q34627645 | MGAT2 deficiency and vertical sleeve gastrectomy have independent metabolic effects in the mouse. |
| Q38974881 | Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology |
| Q42362229 | Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions |
| Q33825213 | Neurobiology of food intake in health and disease |
| Q41884876 | Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies |
| Q36166645 | Peripheral neural targets in obesity |
| Q36512376 | Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q60925246 | Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus |
| Q27321785 | Protection against the Metabolic Syndrome by Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated Receptor γ and Glucagon-Like Peptide-1 |
| Q37681515 | Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluat |
| Q57106873 | Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist |
| Q26829584 | Regulation of energy balance by inflammation: common theme in physiology and pathology |
| Q24563430 | Regulation of glucose homeostasis by GLP-1 |
| Q37185214 | Role of central glucagon-like peptide-1 in stress regulation |
| Q33454248 | Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice. |
| Q36439654 | Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4 |
| Q37134063 | Targeted estrogen delivery reverses the metabolic syndrome |
| Q33787829 | The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats. |
| Q30596646 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss |
| Q38146179 | The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? |
| Q38101677 | The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications |
| Q34355154 | The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism |
| Q41849970 | The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs |
| Q33570118 | Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults |
| Q47347620 | Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. |
| Q41493919 | Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice |
| Q34508419 | Wired on sugar: the role of the CNS in the regulation of glucose homeostasis |
Search more.